ArticleMedicine2026
Comparison of two different topical 0.05% cyclosporine A formulations on ocular surface outcomes following pterygium excision with conjunctival autograft.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A topical 0.05% cyclosporine A (CsA) nanoemulsion formulation was developed to improve tolerability and efficacy. However, its role in preventing recurrence and improving ocular surface parameters after pterygium surgery remains unclear. This study aimed to compare the efficacy and safety of 2 different topical 0.05% CsA formulations following pterygium excision with conjunctival autograft. This retrospective comparative study included patients who underwent pterygium excision with conjunctival autograft using fibrin glue by a single surgeon between January 2021 and June 2024. Postoperatively, patients were administered either 0.05% CsA emulsion (CsA-E; Restasis®, Allergan Inc., Irvine) or 0.05% CsA nanoemulsion (CsA-NE; Cyporin N®, Taejoon Pharm Co., Ltd., Seoul, Republic of Korea) twice daily for 12 months. The primary outcome was the recurrence rate of pterygium at 12 months postoperative. Secondary outcomes included uncorrected (UDVA) and corrected (CDVA) distance visual acuity, tear meniscus height (TMH), and adverse events. A total of 202 eyes (202 patients) was analyzed: 96 in the CsA-E group (60 males, 36 females; mean age, 65.6 ± 8.2 years) and 106 in the CsA-NE group (64 males, 42 females; mean age, 65.2 ± 8.4 years). There were no significant differences in baseline characteristics between the 2 groups. The recurrence rate was 8.3% in the CsA-E group and 3.8% in the CsA-NE group, with no statistically significant difference (P = .235). Postoperative VA outcomes were comparable between the groups; the median CDVA was 0.04 logMAR in both groups (P = .175). Notably, TMH values in both groups significantly decreased compared to baseline (both P <.001), normalizing to within the physiological range, with no significant difference in the magnitude of reduction between the groups (P = .641). No severe adverse events were reported in either group. Both CsA formulations were effective in preventing pterygium recurrence with comparable safety profiles. Additionally, both groups achieved excellent and comparable postoperative VA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.